PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest Abstract #2849

Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Aim(s): Prospectively evaluate: 1) NETest as a surrogate biomarker for RECIST; 2) Correlation of NETest levels, PPQ prediction and treatment efficacy.
Materials and methods: Three independent 177Lu-PRRT-treated GEP-NET and BPNEN cohorts (Rotterdam, Bad-Berka, Meldola: n=122). Treatment response: RECIST1.1 [Responder (stable, partial/complete response) vs Non-Responder]. Blood sampling: pre-PRRT, prior to each cycle and 6 months (median) after PRRT completion. PPQ (positive/negative) and NETest (0-100 score) by PCR. Stable<40; progressive >40). CgA (ELISA) as comparator. Kaplan-Meier survival and Mann-Whitney analyses.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Bodei L, Severi S, Drozdov I, ...
#1916 Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT
Introduction: Prediction of PRRT efficacy is critical. We tested a blood-based multigene NET transcript analysis (NETest) to predict efficacy in 2 PRRT-treated NET cohorts. The algorithm comprises >50 genes + clusters of growth factor signaling (GFS) and metabolism (MTB).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Lisa Bodei
Authors: Bodei L, Kidd M, Singh A, Severi S, ...
Keywords: PRRT, efficacy
#2216 Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker
Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Professor Mark Kidd
#2836 Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Neoplasms: ENETS Center of Excellence Experience
Introduction: There is a substantial clinical unmet need for an accurate blood biomarker for neuroendocrine neoplasms (NENs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Anna Malczewska
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...